During Wednesday’s Current trade, Shares of Hilton Worldwide Holdings Inc (NYSE:HLT), gain 0.75% to $24.28.
A historic property known for its unparalleled Southern hospitality near the heart of downtown Augusta, The Partridge Inn Augusta joined Curio – A Collection by Hilton today. As Hilton Worldwide’s (HLT) rapidly-expanding global collection of distinctive hotels, Curio caters to passionate travelers seeking local discovery and authentic experiences. Dating back more than 100 years, The Partridge Inn Augusta, Curio Collection by Hilton is located in the heart of Augusta’s Summerville district, less than two miles from the Augusta Canal and historic canal boat tours.
Known as “The Grand Hotel of the Classic South,” The Partridge Inn – dating back to the early 1800s – is rich with history and was once a two-story residence for a family from Connecticut. Around 1900, Morris W. Partridge – a seasonal hotel employee in Augusta – bought the property and began offering guest accommodations and expanding the building several times until 1929. After the Great Depression, the inn became a year-round commercial hotel and subsequently an apartment house. The building fell into disrepair after World War II, barely escaping demolition in the 1980s before local residents saved the landmark, thus preserving one of the rich historic legacies of Augusta’s “Hill” area.
Hilton Worldwide Holdings Inc., a hospitality company, owns, leases, manages, develops, and franchises hotels, resorts, and timeshare properties worldwide. The company operates hotels under 12 brand names, counting Hilton Hotels & Resorts, Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Canopy by Hilton, Curio-A Collection by Hilton, DoubleTree by Hilton, Embassy Suites Hotels, Hilton Garden Inn, Hampton Hotels, Homewood Suites by Hilton, Home2 Suites by Hilton, and Hilton Grand Vacations.
Shares of Omeros Corporation (NASDAQ:OMER), declined -2.72% to $13.22, during its current trading session.
Omeros Corporation (OMER) declared additional positive data in the company’s Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body’s organs, most commonly the kidney and brain. OMS721 is Omeros’ lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of TMAs, counting atypical hemolytic uremic syndrome (aHUS).
The Phase 2 trial is designed to enroll primarily aHUS patients but can also enroll patients with thrombotic thrombocytopenic purpura (TTP) and hematopoietic stem cell transplant (HSCT)-related TMA. The trial has fully enrolled the first and second cohorts and is presently concluding the third and final planned cohort of its dose-ranging stage. In each three-patient cohort, OMS721 is dosed for four weeks. Data from the first (low-dose) cohort were released on February 19, 2015. Recently the company is releasing data from its second (mid-dose) cohort and data to date from its third (high-dose) cohort.
Three patients were treated in the second or mid-dose cohort, two of whom have aHUS and one with TTP. Both patients with aHUS were on renal dialysis preceding to and at the time of study enrollment. Based on the positive data from the mid-dose cohort, the high-dose cohort was initiated and an aHUS patient has already accomplished the study treatment period. No patient with HSCT-related TMA has yet accomplished dosing with OMS721. The data referenced for all patients comprise measures to one week following the last dose.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. It markets Omidria for use during cataract surgery or intraocular lens, or replacement surgery.
Endo International plc - Ordinary Shares(NASDAQ:ENDP), during its Wednesday’s current trading session decreased -0.20% to $73.33.
Endo International plc (ENDP) declared that the U.S. District Court for the Southern District of New York has issued a ruling upholding two Endo patents covering OPANA® ER, the Company’s opioid agonist indicated for the administration of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The ruling also determined that Endo’s patents had been infringed by all of the defendants. As a result, it is predictable that the generic version of non-crush-resistant OPANA® ER presently sold by Actavis, the U.S. generics business of Allergan, Inc., will be removed from the market and additional approved but not yet marketed generic versions of the product developed by other generic companies will not be launched in the near term.
Endo International plc, a specialty healthcare company, focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Branded Pharmaceuticals segment provides various branded prescription products, counting Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Fortesta Gel, Supprelin LA, Valstar, Vantas, Sumavel DosePro, Aveed, and Natesto to treat and manage pain and conditions in urology, endocrinology, and oncology.
Finally, SLM Corp (NASDAQ:SLM), decreased -0.74%, to $8.07.
Sallie Mae (SLM), the nation’s saving, planning, and paying for college company, declared a 2015 third-quarter dividend on its Preferred Stock Series B of $0.5075461 per share. The dividend will be paid on September 15, 2015, to stockholders of record at the close of business on September 4, 2015.
SLM Corporation, together with its auxiliaries, operates as a saving, planning, and paying for education company in the United States. The company offers private education loans to students and their families. It also provides banking products, such as high yield savings accounts, money market accounts, and certificates of deposits; and operates a consumer savings network that offers financial rewards on everyday purchases to assist families save for college.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
